Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD, with Zenkuda Demonstrating a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Ef

Go back to Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD, with Zenkuda Demonstrating a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Ef
(NASDAQ: KOD) Delayed: 89.50 -3.47 (3.73%)
Previous Close $92.97    52 Week High $ 
Open $91.14    52 Week Low $ 
Day High $94.64    P/E N/A 
Day Low $89.00    EPS $ 
Volume 577,779